Drug
Nemiralisib clinical trials
Also written GSK2269557.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses Nemiralisib is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute ExacerbationCompletedPhase 2GlaxoSmithKlineNCT02522299Written as GSK2269557
- An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseCompletedPhase 2GlaxoSmithKlineNCT02294734Written as GSK2269557
- Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLICompletedPhase 2GlaxoSmithKlineNCT02593539Written as Nemiralisib
- A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of NemiralisibCompletedPhase 1GlaxoSmithKlineNCT03398421Written as Nemiralisib
- Absorption & Elimination of Radiolabelled GSK2269557CompletedPhase 1GlaxoSmithKlineNCT03315559Written as [14C]-GSK2269557 IV infusion
- Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT03189589Written as GSK2269557 500 µg
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2GlaxoSmithKlineNCT02130635Written as GSK2269557 100 MCG
- A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled AsthmaCompletedPhase 2GlaxoSmithKlineNCT02567708Written as GSK2269557 DPI
- Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557CompletedPhase 1GlaxoSmithKlineNCT01462617Written as GSK2269557
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT01762878Written as GSK2269557
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT02691325Written as GSK2269557 ELLIPTA DPI
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT02972905Written as GSK2269557 ELLIPTA DPI
Codes
What other systems call Nemiralisib · ClinicalTrials.gg INT001035
- MeSH (NLM) C000629641NemiralisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) OEP8JJ3OZRNEMIRALISIBConfirmed FDA, NLM
- NCI Thesaurus C174798NemiralisibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629641 | Nemiralisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | OEP8JJ3OZR | NEMIRALISIB | Confirmed FDA, NLM |
| NCI Thesaurus | C174798 | Nemiralisib | One source FDA |
Also registered as nemiralisib hydrochloride (UNII II4WQU7U3O).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.